Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Apr 15, 2025; 17(4): 103855
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103855
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103855
Table 3 Comparison of grade 1-2 adverse reactions, n (%)
| Adverse reaction | Control (n = 54) | Observation (n = 50) | χ2 | P value |
| Leukopenia | 22 (40.74) | 20 (40.00) | 0.005 | 0.938 |
| Neutropenia | 13 (24.07) | 19 (38.00) | 2.363 | 0.124 |
| Lymphopenia | 28 (51.85) | 29 (58.00) | 0.396 | 0.529 |
| Thrombocytopenia | 29 (53.70) | 25 (50.00) | 0.142 | 0.705 |
| Hemoglobin reduction | 23 (42.59) | 22 (44.00) | 0.020 | 0.885 |
| Gastrointestinal reaction | 20 (37.04) | 17 (34.00) | 0.104 | 0.746 |
| Abnormal liver function | 9 (16.67) | 8 (16.00) | 0.008 | 0.927 |
| Pneumonia | 4 (7.41) | 3 (6.00) | 0.011 | 0.916 |
| Hypothyroidism | 0 (0.00) | 6 (12.00) | 4.846 | 0.027 |
- Citation: Zhang SH, Li W, Chen XY, Nie LL. Combining immune checkpoint inhibitors with standard treatment regimens in advanced human epidermal growth factor receptor-2 positive gastric cancer patients. World J Gastrointest Oncol 2025; 17(4): 103855
- URL: https://www.wjgnet.com/1948-5204/full/v17/i4/103855.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i4.103855